{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T20:28:18Z","timestamp":1780086498237,"version":"3.54.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T00:00:00Z","timestamp":1679270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The field of geriatric oncology has made significant progress in recent decades, but there are still missed opportunities in important areas of research. One issue is the underrepresentation of older patients, especially those aged 75 years and older, in clinical trials. This has resulted in a lack of high-quality data for the care of this population, and the American Society of Clinical Oncology has called for an increase in the evidence base for older patients with cancer. The second missed opportunity is the chance to gather important knowledge from older patients participating in clinical trials, such as medications, social support, insurance, and financial information. These data can be easily collected and incorporated into the trial design to enhance the information available to researchers and clinicians. The third missed opportunity is the chance to robustly analyze and report clinical trial data for the benefit of geriatric oncology research. Many trials only report a median age and range, which is a disservice to both the participants and the patients who will be treated based on the study results. To advance geriatric oncology research, the necessary data need to be collected, analyzed, and reported through appropriate representation of older patients, collection of essential information, and thorough analysis and communication of results. Clinical trial design needs to include geriatric baseline parameters, and Cancer Therapy Evaluation Program (CTEP) has modified its template to include these parameters.<\/jats:p>","DOI":"10.1093\/oncolo\/oyad072","type":"journal-article","created":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T18:36:27Z","timestamp":1679337387000},"page":"373-375","source":"Crossref","is-referenced-by-count":8,"title":["Missed Opportunities in Geriatric Oncology Research"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4146-6192","authenticated-orcid":false,"given":"Stuart M","family":"Lichtman","sequence":"first","affiliation":[{"name":"Wilmot Cancer Institute Geriatric Oncology Research Group, University of Rochester , Rochester, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,20]]},"reference":[{"issue":"12","key":"2023050815242453500_CIT0001","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1056\/NEJMp2106089","article-title":"Treatment of older adults with cancer\u2014addressing gaps in evidence","volume":"385","author":"Bertagnolli","year":"2021","journal-title":"N Engl J Med"},{"issue":"17","key":"2023050815242453500_CIT0002","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1200\/JCO.2012.41.6727","article-title":"Under-representation of older adults in cancer registration trials: known problem, little progress","volume":"30","author":"Scher","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"2023050815242453500_CIT0003","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jgo.2019.07.017","article-title":"Barriers to clinical trial enrollment of older adults with cancer: A qualitative study of the perceptions of community and academic oncologists","volume":"11","author":"Sedrak","year":"2020","journal-title":"J Geriatr Oncol"},{"issue":"1","key":"2023050815242453500_CIT0004","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3322\/caac.21638","article-title":"Older adult participation in cancer clinical trials: A systematic review of barriers and interventions","volume":"71","author":"Sedrak","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"32","key":"2023050815242453500_CIT0005","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1200\/JCO.2015.63.0319","article-title":"Improving the evidence base for treating older adults with cancer: American Society of Clinical Oncology statement","volume":"33","author":"Hurria","year":"2015","journal-title":"J Clin Oncol"},{"issue":"22","key":"2023050815242453500_CIT0006","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","article-title":"Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO Guideline for Geriatric Oncology","volume":"36","author":"Mohile","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"2023050815242453500_CIT0007","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jgo.2019.07.013","article-title":"Cores for geriatric oncology infrastructure in the Cancer and Aging Research Group: biostatistics, epidemiology, and research design (the analytics core)","volume":"11","author":"Sedrak","year":"2020","journal-title":"J Geriatr Oncol"},{"issue":"10","key":"2023050815242453500_CIT0008","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1080\/13543784.2017.1369043","article-title":"Considerations for clinical trial design in older adults with cancer","volume":"26","author":"Soto-Perez-De-Celis","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"issue":"4","key":"2023050815242453500_CIT0009","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jgo.2016.02.005","article-title":"Pragmatic study designs for older adults with cancer: Report from the U13 conference","volume":"7","author":"Nipp","year":"2016","journal-title":"J Geriatr Oncol"},{"issue":"4","key":"2023050815242453500_CIT0010","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jgo.2016.04.007","article-title":"Designing exercise clinical trials for older adults with cancer: recommendations from 2015 Cancer and Aging Research Group NCI U13 Meeting","volume":"7","author":"Kilari","year":"2016","journal-title":"J Geriatr Oncol"},{"issue":"24","key":"2023050815242453500_CIT0011","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1200\/JCO.2013.55.0418","article-title":"Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations","volume":"32","author":"Hurria","year":"2014","journal-title":"J Clin Oncol"},{"issue":"29","key":"2023050815242453500_CIT0012","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1200\/JCO.2013.49.6125","article-title":"End points and trial design in geriatric oncology research: a joint European organisation for research and treatment of cancer--Alliance for Clinical Trials in Oncology--International Society Of Geriatric Oncology position article","volume":"31","author":"Wildiers","year":"2013","journal-title":"J Clin Oncol"},{"issue":"25","key":"2023050815242453500_CIT0013","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1200\/JCO.2017.72.8170","article-title":"Time to stop saying geriatric assessment is too time consuming","volume":"35","author":"Hamaker","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10314","key":"2023050815242453500_CIT0014","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(21)01789-X","article-title":"Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study","volume":"398","author":"Mohile","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"2023050815242453500_CIT0015","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2011.41.0696","article-title":"Call for changes in clinical trial reporting of older patients with cancer","volume":"30","author":"Lichtman","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"2023050815242453500_CIT0016","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jgo.2019.12.007","article-title":"The underreporting of phase III chemo-therapeutic clinical trial data of older patients with cancer: a systematic review","volume":"11","author":"BrintzenhofeSzoc","year":"2020","journal-title":"J Geriatr Oncol"},{"key":"2023050815242453500_CIT0017","author":"CTEP Cancer Therapy Evaluation Program."},{"key":"2023050815242453500_CIT0018","author":"U.S. Food & Drug Administration."},{"key":"2023050815242453500_CIT0019","author":"Lichtman"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/5\/373\/50247552\/oyad072.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/5\/373\/50247552\/oyad072.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T16:11:55Z","timestamp":1683562315000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/5\/373\/7081220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,20]]},"references-count":19,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,3,20]]},"published-print":{"date-parts":[[2023,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad072","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5,1]]},"published":{"date-parts":[[2023,3,20]]}}}